Arrowhead Provides Response to New Minority Shareholder Announcement

Home/Newsroom/

Arrowhead Provides Response to...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today responded to the

announcement by Silence Therapeutics plc that it acquired, in the

open-market, an equity stake of 6,000,359 Arrowhead shares, representing

8.4% of the common shares outstanding. Arrowhead was advised of this

just prior to the announcement by Silence.

There have been no discussions about any potential transaction between

the two companies. Arrowhead’s plans to develop its RNAi-based drug

candidates ARO-HBV, ARO-AAT, ARO-F12, ARO-HIF2, ARO-LPA, ARO-AMG1, and

other undisclosed programs, are unchanged and unaffected by this

announcement. The company will also continue to seek partnerships and

collaborations that maximize the value of its assets, as such

opportunities may arise in the future.

Arrowhead president and CEO, Chris Anzalone, remarked, “We remain

focused on advancing our programs in a way that maximizes stockholder

value. While we welcome Silence as a stockholder, its recently announced

stake in Arrowhead does not change our focus or strategic plans in any

way.”

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing.

For more information, please visit www.arrowheadpharma.com,

or follow us on Twitter @ArrowheadPharma.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including the safety and efficacy of our product

candidates, the duration and impact of regulatory delays in our clinical

programs, our ability to finance our operations, the future success of

our scientific studies, our ability to successfully develop drug

candidates, the timing for starting and completing clinical trials,

rapid technological change in our markets, and the enforcement of our

intellectual property rights. Our most recent Annual Report on Form 10-K

and subsequent Quarterly Reports on Form 10-Q discuss some of the

important risk factors that may affect our business, results of

operations and financial condition. We assume no obligation to update or

revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead

Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investor

Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowheadpharma.com
Media:
Russo

Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media